Microvascular Function in Patients Undergoing Transcatheter Aortic Valve Implant (TAVI) for Sever… (NCT05326126) | Clinical Trial Compass
CompletedNot Applicable
Microvascular Function in Patients Undergoing Transcatheter Aortic Valve Implant (TAVI) for Severe Symptomatic Aortic Stenosis: Association With Myocardial Fibrosis
Italy75 participantsStarted 2021-07-08
Plain-language summary
Microvascular function in patients undergoing Transcatheter Aortic Valve Implant (TAVI) for severe symptomatic aortic stenosis: association with myocardial fibrosis
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
• All patients referred to IRCCS Ospedale San Raffaele who are candidates to receive a TAVI implant for severe, symptomatic aortic stenosis under current appropriateness criteria and clinical practice guidelines will be considered eligible to take part in the study
Exclusion Criteria:
* Age \<18 years
* Inability to express informed consent to take part in the present study.
* Pregnancy or lactation
* Pre-existing known disease determining a prognosis quo ad vitam shorter than the follow up of the present study
* Significant chronic kidney disease (estimated glomerular filtration rate \<30 ml/min)
* Known significant epicardial coronary artery stenosis
* Known contraindication to adenosine administration:
* Known allergic reactions
* Second or third degree atrioventricular block before the procedure (in absence of a functional permanent pacemaker)
* Long QT syndrome
* Unstable angina
* Severe hypotension
* Acutely decompensated heart failure
* Chronic obstructive pulmonary disease with bronchospasm
* Concomitant use of dypiridamole